Suboptimal use of ovarian function suppression in very young women with early breast cancer: a real-world data study

Simple item page
dc.catalogadorjlo
dc.contributor.authorHeredia Castro, Ana Manuela
dc.contributor.authorWalbaum García, Benjamín Vicente
dc.contributor.authorVidal, María
dc.contributor.authorItriago Giménez, Laura Morella
dc.contributor.authorCamus Appuhn, Mauricio Gonzalo
dc.contributor.authorDomínguez Covarrubias, Francisco José
dc.contributor.authorManzor, Manuel
dc.contributor.authorMartínez, Raúl
dc.contributor.authorMurature, Geraldine
dc.contributor.authorMuñiz Muñoz, María Sabrina
dc.contributor.authorNavarro, Marisel
dc.contributor.authorGuerra, Constanza
dc.contributor.authorMerino Lara, Tomás Rodrigo
dc.contributor.authorMedina Araya, Lidia Marjorie
dc.contributor.authorIbáñez Cáceres, Carolina
dc.contributor.authorRamírez Parada, Karol Lilia
dc.contributor.authorAcevedo Claros, Francisco Nicolás
dc.contributor.authorSánchez Rojel, César Giovanni
dc.date.accessioned2024-03-27T13:32:02Z
dc.date.available2024-03-27T13:32:02Z
dc.date.issued2024
dc.description.abstractPurpose The incidence of breast cancer in young women (BCYW) has increased in recent decades. Malignant disease in this subset is characterized by its aggressiveness and poor prognosis. Ovarian function suppression (OFS) in these patients improves survival especially in hormone receptor-positive (HR +) cases. The Regan Composite Risk (RCR) is a prognostic tool to identify high-risk HR + BC candidates for OFS. Our study sought to characterize a Chilean cohort of early HR + BCYW assessing the use of OFS and its related prognosis and the utility of RCR in our patients.MethodsThis was a retrospective population cohort study that included ≤ 35-year-old early HR + /human epidermal growth factor receptor 2 -negative (HER2-) BC patients treated between 2001 and 2021. Analysis included clinical-pathological characteristics, treatment strategies, and survival. Also, we evaluated the association between RCR and survival.ResultsA total of 143 patients were included into our study, representing 2.9% of all early BC cases in our registry. Median age was 31 years old (range: 19–35). Most patients (93%) received endocrine therapy (ET). Of these, 18% received OFS. No survival differences were observed among treatment strategies. Median RCR score for patients treated with CT plus ET was significantly higher vs. ET alone (2.95 vs. 1.91; p = 0.0001). Conversely, patients treated with tamoxifen alone had significantly lower RCR scores vs. OFS (2.72 vs. 3.14; p = 0.04). Higher RCR scores were associated with poorer overall survival.ConclusionLess than 20% of very young women with early HR + /HER2-BC in our cohort received OFS, in most cases, this involved surgical oophorectomy. RCR score was higher in patients that underwent CT and OFS and was associated with survival, regardless of treatment. We confirm the RCR score as a valuable prognostic tool to identify high-risk BC patients who could benefit from OFS.
dc.format.extent7 páginas
dc.fuente.origenORCID
dc.identifier.doi10.1007/s10549-023-07117-5
dc.identifier.issn0167-6806
dc.identifier.urihttp://dx.doi.org/10.1007/s10549-023-07117-5
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/84753
dc.information.autorucEscuela de Medicina; Acevedo Claros, Francisco Nicolas; 0000-0003-3482-7746; 119540
dc.information.autorucEscuela de Medicina; Heredia Castro, Ana Manuela; S/I; 218714
dc.information.autorucEscuela de Medicina; Walbaum García, Benjamín Vicente; 0000-0003-2314-5360; 163702
dc.information.autorucEscuela de Medicina; Itriago Giménez, Laura Morella; S/I; 167362
dc.information.autorucEscuela de Medicina; Camus Appuhn, Mauricio Gonzalo; 0000-0002-8409-5240; 100235
dc.information.autorucEscuela de Medicina; Domínguez Covarrubias, Francisco José; S/I; 630
dc.information.autorucEscuela de Medicina; Muñiz Muñoz, María Sabrina; S/I; 1023831
dc.information.autorucEscuela de Medicina; Merino Lara, Tomás Rodrigo; S/I; 119017
dc.information.autorucEscuela de Enfermería; Medina Araya, Lidia Marjorie; S/I; 18566
dc.information.autorucEscuela de Medicina; Ibáñez Cáceres, Carolina; S/I; 146063
dc.information.autorucEscuela de Medicina; Ramírez Parada, Karol Lilia; 0000-0002-9143-321X; 1005837
dc.information.autorucEscuela de Medicina; Acevedo Claros, Francisco Nicolás; 0000-0003-3482-7746; 119540
dc.information.autorucEscuela de Medicina; Sánchez Rojel, César Giovanni; 0000-0002-2920-108X; 135644
dc.language.isoen
dc.nota.accesocontenido parcial
dc.pagina.final179
dc.pagina.inicio173
dc.revistaBreast Cancer Research and Treatment
dc.rightsacceso restringido
dc.subjectBreast neoplasm
dc.subjectReceptors
dc.subjectEstrogen
dc.subjectOophorectomy
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.titleSuboptimal use of ovarian function suppression in very young women with early breast cancer: a real-world data study
dc.typeartículo
dc.volumen203
sipa.codpersvinculados119540
sipa.codpersvinculados218714
sipa.codpersvinculados163702
sipa.codpersvinculados167362
sipa.codpersvinculados100235
sipa.codpersvinculados630
sipa.codpersvinculados1023831
sipa.codpersvinculados119017
sipa.codpersvinculados18566
sipa.codpersvinculados146063
sipa.codpersvinculados1005837
sipa.codpersvinculados135644
sipa.trazabilidadORCID;2024-03-25
Files
Collections
Artículos de revistas